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Abstract
Background Although the incidence of atrial fibrillation (AF)
progressively increases with age, the vast majority of AF
ablation is done in middle-aged patients. We evaluated the
feasibility and safety of catheter ablation in patients older than
65 years of age with paroxysmal and persistent AF.
Methods Out of a total of 230 consecutive AF ablation
procedures, 45 patients were older than 65 years of age and
underwent 53 procedures. The ablation strategy consisted of
wide-area circumferential lines around both ipsilateral pulmo-
nary veins using a three-dimensional mapping system.
Results The mean age was 69±3.5 years (35 males). The
mean duration for AF was 8.7±6.5 years. Thirty-nine had
paroxysmal and six persistent AF despite use of 1.38±0.77
antiarrhythmic drugs. All patients had a structurally normal
heart. Eleven had systemic hypertension. Mean procedure
time was 187±33 min. Acute procedural success rate with
abolition of all pulmonary vein potentials was achieved in
all patients. Pericardial tamponade requiring percutaneous
drainage occurred in one (1.9%) patient. There were no
cardioembolic events. Among the 43 patients whose
clinical outcome was assessed at 6 months, 34 (79%) had
a significant reduction (>90%) of the total symptomatic AF
burden, compared to pre-ablation, with a complete lack of
symptomatic AF in 32 (74%) patients. The success rate was
higher for patients with paroxysmal versus persistent AF
(81 vs. 67%). Six patients (11%) underwent repeat
procedures.
Conclusions Catheter ablation is a safe and effective
treatment for patients over the age of 65 years with
symptomatic, drug-refractory AF. Therefore, patients
should not be excluded from undergoing AF catheter
ablation on the basis of age alone.
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1 Background
Atrial fibrillation (AF) is the most common of all cardiac
arrhythmias with an incidence and prevalence to be on
the rise. AF is a disease of the elderly with a prevalence
increasing with age. Up to 5% of the population over the
age of 65 years are suffering from AF [1]. The median
age of a patient with AF is 75 years and 70% of the AF
patients are aged 65 to 85 years of age [2, 3]. Disease
management is challenged in elderly AF patients by
frequent comorbidities including hypertension, congestive
heart failure, left ventricular hypertrophy, coronary artery
disease, and diabetes mellitus placing them at increased
risk for thromboembolic complications with AF [4], side
effects, and pro-arrhythmias.
Radiofrequency catheter ablation is widely performed
as an effective treatment for recurrent, drug-resistant AF
[5–8]. Ablation techniques have improved and the com-
plication rate has decreased [9–12]. As a result, referrals
of elderly patients for catheter ablation of AF are on the
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Table 1 Patient assessment form
1. Have you had any of the following symptoms?      
Occasional skips and jumps in the heart? Y / N    (please circle) 
Regular racing heart beat? Y / N    (please circle) 
Irregular racing heart beat? Y / N    (please circle) 
2. Please chart the amount of racing you have had below (months after ablation):    
4th month 5th month 6th month 
Number of episodes? 
How long do they last? 
3. Did you require treatment in hospital?      medication only        electrical cardioversion 
4. Do they feel the same as before the procedure?    Y / N      (please circle) 
    If not, why? 
Not as fast Symptoms not as bad 
Regular (was irregular before) Shorter duration 
Other .. 
5. Overall, how do you feel compared to before the procedure?  (place a mark on the line) 
   Worse Same        Improved by: 
    50%        75%  90% 100%  
6. Are you or your doctor considering a repeat ablation procedure?  Y / N 
7. Are you taking fewer medications for AF than before the procedure? Y / N 
8. Are you still taking warfarin (also called coumadin)? Y / N 
9. Have you had a pacemaker implanted since your ablation? Y / N
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rise. However, few elderly patients were included in prior
AF catheter ablation studies. With increasing life expectancy,
the elderly are the most rapidly expanding portion of our
population making AF an even more important public
health concern. Catheter ablation for the elderly could be
an important treatment strategy after failed antiarrhythmic
drug therapy. We aimed to assess feasibility, safety, and
outcome of AF catheter ablation procedure in an elderly
patient population.
2 Methods
Study patients Consecutive patients over the age of 65 years
with symptomatic paroxysmal and persistent AF undergo-
ing a percutaneous catheter ablation procedure at the Royal
Jubilee Hospital in Victoria B.C. (Canada) were included in
this study. None of the patients had a significant structural
heart disease. Demographic and clinical data were collected
prior to the procedure. All patients gave informed consent
prior to the procedure.
Ablation procedure All patients underwent a wide-area
circumferential pulmonary vein isolation for paroxysmal AF
and additional linear lesions for persistent AF. For that
purpose, three femoral vein sheaths were inserted under local
anesthesia. A 6F steerable decapolar electrophysiology
catheter Livewire™ (St. Jude Medical Inc., St. Paul, MN,
USA) was placed into the coronary sinus. After double
transseptal puncture performed using a BRK™ transseptal
needle (St. Jude Medical Inc., St. Paul, MN, USA), a 5F
circular decapolar catheter SC™ (St. Jude Medical Inc., St.
Paul, MN, USA) and a 7F non-irrigated 4-mm tip bi-
directional ablation catheter RF Conductr™ MC (Medtronic
Inc., Minneapolis, MN, USA) were passed transseptally
through two 8F transseptal guiding introducers Swartz™
SL1™ (St. Jude Medical Inc., St. Paul, MN, USA). The
catheter ablation was performed using radiofrequency energy
under Ensite NavX™mapping system (St. Jude Medical Inc.,
St. Paul, MN, USA) guidance.
The ablation strategy consisted of continuous wide-area
circumferential lines around both ipsilateral pulmonary
veins. Lesions were delivered for 30 s, at 35 W for a
maximum target temperature of 58°C. For patients with
persistent AF, additional linear lesions were performed: a
left atrial roof line connecting both upper left and right
pulmonary veins and a left atrial isthmus line between the
mitral valve annulus and the left inferior pulmonary vein.
The additional left atrial lines were not routinely mapped
and checked for conduction block and no ablation within
the coronary sinus was performed. The endpoint of the
procedure in both paroxysmal and persistent AF patients
was electrical isolation of all pulmonary veins, which was
assessed using the circular spiral catheter. No systematic
mapping was performed in order to identify non-pulmonary
vein or pulmonary vein triggers of AF. The procedure was
performed under conscious sedation using midazolam and
fentanyl. This ablation protocol did not differ from the
ablation approach in younger AF patients treated in our
institution.
Anticoagulation strategy Warfarin was discontinued 3 days
prior to the procedure to allow INR to drop in a
subtherapeutic range the day of the procedure (INR<2.0).
After insertion of the transseptal catheters, therapeutic
anticoagulation was initiated with a bolus of intravenous
heparin (100 IU/kg bodyweight). Activated clotting time
(ACT) was monitored in 30-min intervals followed by
additional boluses of heparin to keep the ACT with a target
of 300 s. Oral anticoagulation was resumed on the same
day of the procedure for at least 3 months.
The clinical outcome after the ablation procedure was
assessed using a patient assessment form at 6 months after
the intervention (Table 1).
3 Results
Out of a total of 230 consecutive AF ablation procedures,
45 patients were older than 65 years of age and underwent
Table 2 Patient characteristics
n=45
Age (years) 69±3.5
Sex (male) 35 (78%)
Type of AF
Paroxysmal AF 39 (87%)
Persistent AF 6 (13%)
History of AF (years) 8.7±6.5
Number of AAD 1.38±0.77
AAD antiarrhythmic drug, LA left atrium, EF ejection fraction
Table 3 Procedural statistics
n=53
Average procedure time (minutes) 187±33
Fluoroscopy time (minutes) 43±12
Major complications
Thromboembolic event and stroke None
Pericardial tamponade 1 (1.9%)
Vascular access complications None
ACT activated clotting time, IU international units
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53 procedures. Of the 53 ablation procedures were eight
repeat procedures. The mean age of our population was
69±3.5 years. The patient characteristics are shown in
Table 2. All had a structurally normal heart. The procedural
characteristics are shown in Table 3. The mean procedure
time was 187±33 min. Acute procedural success rate with
abolition of all pulmonary vein potentials was achieved in
all patients. Pericardial effusion requiring percutaneous
drainage occurred in one (1.9%) patient. There were neither
acute nor late peripheral or cerebral thromboembolic events
observed. None of the procedures were complicated by
vascular access complications requiring transfusion or
surgical interventions. Among the 43 patients whose
clinical outcome was assessed at 6 months, 34 (79%) had
a significant reduction of the total symptomatic AF
episodes, compared to pre-ablation, with a complete lack
of symptomatic AF in 32 (75%) patients and partial success
(defined as >90% improvement in symptoms) in the
remaining two (4%). The success rate was higher for
patients with paroxysmal versus persistent AF (81% vs.
67%). Six patients (11%) underwent repeated procedures.
4 Discussion
The majority of AF patients seeking medical treatment
are in the elderly age group which is often complicated
by comorbidities making antiarrhythmic drug treatment
difficult. Because of hypertension, congestive heart
failure, left ventricular hypertrophy, and coronary artery
disease antiarrhythmic drug treatment often fails due to
side effects, pro-arrhythmia, or poor rhythm control.
Since few years now radiofrequency catheter ablation is
widely performed as an effective treatment for recurrent,
drug-refractory AF. However, few elderly patients were
included in prior AF catheter ablation studies and the
current guidelines for catheter ablation of AF recommend
a conservative approach in the elderly patient population
in the absence of clinical data [13].
Our study results suggest that catheter ablation of AF in
patients aged 65 years or more can be performed with
success rates comparable to those in younger patients
without an increase in complication rate. Successful
maintenance of a stable sinus rhythm could be achieved
in nearly 80% of this patient population with a mean age of
69 years. The rate for major complication was low with one
patient (1.9%) having an acute pericardial effusion requir-
ing percutaneous drainage. No other major complications
including death, thromboembolism, atrioesophageal fistula,
or vascular access complications occurred. Zado et al. [14]
found similar success and complication rates in patients’
age group over 65 years. Interestingly, they were more
likely to be women (up to 56% in the age group over
75 years). Patients over age 80 years in the paper of Tan et
al. [15] were less likely to undergo a repeat procedure than
younger patients, but again the success and complication
rates were not significantly different in the age group over
80 years than in those 60–69 years (70% versus 74% for
success rate). Another study by Bunch et al. [16] found also
no increased risk of periprocedural complications in 35
patients aged 80 years and older.
Limitations This is an observational cohort study, and is
not a prospective, randomized trial. In the absence of a
direct randomized comparison of an invasive versus non-
invasive approach in the elderly AF patients, limited
conclusions regarding outcome and safety of the catheter
ablation procedure in this population can be made.
Furthermore, the freedom of AF was assessed based on
symptoms reported by the patients only, and no clear
uniform long-term rhythm monitoring was performed in
all patients.
5 Conclusions
Catheter ablation for AF can be performed in elderly
patients group aged 65 years and more with normal hearts
and predominantly paroxysmal AF, with comparable
success and complication rates to those in younger patients.
Therefore, ablation therapy should be considered as an
appropriate therapeutic option for this patient group.
Patients should not be excluded from undergoing AF
catheter ablation on the basis of age alone.
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